{"entity":{"id":"nct03899636","kind":"trial","name":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of Modified FOLFIRINOX Regimen in pancreatic ductal adenocarcinoma, run by Angiodynamics, Inc., active and no longer recruiting.","summary":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer is a phase 3 interventional study registered as NCT03899636 by Angiodynamics, Inc., with 528 participants enrolled, started 2021-02-23 and due to reach its primary completion in 2025-04. Interventions recorded: Modified FOLFIRINOX Regimen and NanoKnife System.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03899636","url":"https://clinicaltrials.gov/study/NCT03899636"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03899636","phase":"3","setting":"A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma","sponsor":"Angiodynamics, Inc.","enrolled":528,"outcomes":[]},"route":"/trials/nct03899636/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}